In triple-negative breast cancer (MDA-MB-231 and 4T1) cells, emodin targets nuclear receptor corepressor 2 (NCOR2) to upregulate seryl-tRNA synthetase (SerRS), suppressing VEGFA transcription and angiogenesis [440]. Here, NCOR2 is linked to triple-negative breast carcinoma.